YD Global Life Science, Inc.

Bronwyn Brophy has an impressive track record as a leader of global Life science and Medtech businesses. The Board of directors find Bronwyn Brophy to be an exceptional candidate to effectuate Vitrolife's strategy to reach the company's full potential and thereby create increased shareholder value. GOTHENBURG, Sweden, Feb. 1, 2023 /PRNewswire/ -- Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson. The last years within Thermo Fischer Bronwyn Brophy was heading the Immunodiagnostics Division globally and before that served as President of the EMEA region. Bronwyn Brophy will join the company at the latest on 1 August 2023. As notified 12 September 2022, Thomas Axelsson will leave his position as CEO. This is expected to occur 31 March 2023. At that time Jón Sigurdsson, today Chairman of the board, will assume the position as interim CEO until Bronwyn Brophy starts her appointment. Consequently, the board of directors has appointed the current board member Henrik Blomquist as chairman of the board until the annual general meeting 27 April 2023. Jón Sigurdsson, chairman of the board, says: "I am very pleased that we have been able to assign Bronwyn Brophy as CEO. She has an extensive experience of developing businesses and has a wide international experience which is important for Vitrolife. Again, I would like to thank Thomas Axelsson for an excellent job done for Vitrolife and for our great cooperation." Bronwyn Brophy comments the appointment: "I am very honored to the appointment as new CEO of Vitrolife. I believe the company has a very exciting future with great growth potential with strong distributors and global partners". Contact persons: Thomas Axelsson, CEO, phone: +46 31 721 80 01 Patrik Tolf, CFO, phone: +46 31 766 90 21 This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.15 am CET on February 1, 2023. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails. The following files are available for download: SOURCE Vitrolife AB (publ)

NEW YORK & CARLSBAD, Calif.--( BUSINESS WIRE )--In its 15 th year, Biotech Showcase™ , co-produced by Demy-Colton and EBD Group , welcomed more than 3,200 attendees, more than 1,100 investors, and more than 400 presenting companies. Following a 2-year shift to virtual, the conference was held in-person in San Francisco from January 9-11, 2023, for the first time since 2020, with a virtual partnering component the following week from January 18-19. The event allowed attendees to explore impactful trends, engage industry experts, discover innovative companies, and meet motivated investors. Among attendees were nearly 70 members of the press. In an annual event meant to drive the future of drug discovery and development, this year’s participants engaged in 24 program sessions and panels, which included more than 115 speakers. Attendees also engaged in more than 7,000 partnering meetings delivered through the partneringONE® meeting platform. The 2023 program featured insights from top investors and biopharma executives across a broad spectrum of expertise. Speakers examined numerous relevant topics, from how COVID-19 accelerated all things digital, to the biopharma industry advancing drug discovery and manufacturing to improve patient outcomes, and provided updates in critical therapeutic areas such as CNS, cell and gene therapy, women’s health, and oncology. The full agenda is available here . Some especially timely topics related to current economic forces and industry change, including: Headwinds or Not: Moving Forward Despite the Challenging Environment The Inflation Reduction Act (IRA): The Dawn of a New Era - What Will it Mean for Innovation? Women’s Health: A Traditionally Underfunded and Unrecognized Area, but Times Are Changing Finance: The Outlook for the BioPharma Sector in ‘23 and Beyond A list of all speakers is available here , with many high-profile leaders, including the following: Anne Bailey, Director, Clinical Tech Innovation at U.S. Department of Veterans Affairs Dawn Bell , Global Development Head, Strategic Partnerships, Novartis Jennifer Garrison , Co-Founder & Director, Global Consortium for Reproductive Longevity & Equality and Assistant Professor, Buck Institute Walter Greenleaf , Distinguished Visiting Scholar, Stanford University’s MediaX Program Paul Hastings , President & CEO, Nkarta Therapeutics & Chair, Biotechnology Innovation Organization Chihiro Hosoya, Head of Venture Management and Business Development, Astellas Ben Johnson , Head of Early Stage, Silicon Valley Bank Philippe Lopes-Fernandes , Executive Vice President, Chief Business Officer, Ipsen Regina Salvat , Principal, Sofinnova Investments Sze-Wee Tan , Assistant Chief Executive, Innovation & Enterprise Group, Agency for Science & Technology Research (A*STAR) “It has been exciting to host Biotech Showcase in-person for the first time since 2020,” says Sara Jane Demy , Founder and CEO, Demy-Colton. “We’re thrilled that we could bring industry leaders, top investors, biotech and pharmaceutical companies together to discuss today’s most relevant opportunities and challenges, fuel investment to drive innovation, and build relationships to accelerate drug development.” Demy-Colton and EBD Group have provided registered attendees with on-demand access to all company presentations and other content for the three months following the event, through April 20, 2023, for all conference registrants. Those interested in accessing program content can simply log in with their registration information. “Biotech Showcase remains one of the largest investor conferences for the life sciences industry and is a particularly pivotal touchpoint for those looking for partnerships and investment,” says Tina Elder , Global Managing Director, EBD Group US . “We are very pleased with the amazing response from presenting companies, investors, and existing and potential partners, which resulted in a remarkable level of engagement and meeting requests.” For more information, please visit www.biotechshowcase.com or follow us on Twitter at @Demy_Colton and @EBDGroup. About Demy-Colton Since 2008, Demy-Colton has been at the forefront of building networks between leaders from innovative biotech companies and industry stakeholders to examine and address biotech opportunities and challenges and deliver on the promise of transformational science. Demy-Colton achieves this with unique meeting platforms that facilitate networking and biotech community development on an international scale. Aside from Biotech Showcase™, its investor and specialized events include BioFuture™, CEO Summit Europe™, CEO Summit™, Demy-Colton Virtual Salons, and CEO Virtual Dialogues. Its events build networking communities that transcend geographical boundaries and establish ongoing, high-value relationships among the industry’s top decision-makers, investors, and thought leaders. Demy-Colton sets a unique stage where investment, learning, and growth thrive. Its events spur introductions and thoughtful conversations. In turn, inspiration, ideas, and opportunities for investment flow. About EBD Group EBD Group’s overriding mission is to help collaborations get started across the life sciences value chain. Our range of partnering conferences has grown to become the industry's largest and most productive conference platform. Each of our landmark events held in key life sciences markets worldwide is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today our events (BIO-Europe®, BIO-Europe Spring®, BioPharm America™, Biotech Showcase™, China Showcase, Digital Medicine & Medtech Showcase, ChinaBio® Partnering Forum, Rare Disease Innovation and Partnering Summit, and BioEquity Europe) annually attract more than 15,000 senior life sciences executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.